Lab21 hires cfo
Susan Lowther joins Cambridge, UK-based firm
Lowther has spent more than 20 years in the pharmaceutical, biotech and healthcare industries and has held senior management positions at BioWisdom, RiboTargets, Lonza Biologics, Celltech and Monsanto.
Graham Mullis, Lab21 ceo, said: ‘Susan’s financial and life sciences industry expertise, particularly in the area of acquisitions, will be essential as we continue to develop the company.’
You may also like
Finance
Syngene International extends long-term research collaboration with Bristol Myers Squibb until 2035
Syngene International, a global contract research, development, and manufacturing organisation (CRDMO), announces the extension of its long-standing strategic collaboration with Bristol Myers Squibb through 2035
Finance
Novo Nordisk Foundation commits DKK 5.5bn to boost European life sciences innovation
The long-term funding will enable the BioInnovation Institute to expand into new scientific fields and European markets, strengthening translation of academic research into commercial life sciences innovation
Finance
European life sciences investors kick off 2026 with targeted bets on immunity, oncology and metabolic health
From thymus regeneration and ECM-targeted oncology to fast-scaling metabolic health technology, three European companies secure fresh capital as investors double down on differentiated science with clear commercial momentum
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.